An Introduction to Gastrointestinal Cancers
Despite advances in radiotherapy, chemotherapy, and targeted therapy for gastrointestinal cancers, the disease has high recurrence rates and a poor prognosis. However, increased understanding of molecular biology has enabled significant progress in the management of oesophageal, gastric, liver, colorectal and pancreatic malignancies. Immunotherapies such as PD1 inhibitors plus HER-targeted therapies have improved survival in several gastrointestinal tumour types, while PARP inhibitors have been introduced as first-line maintenance treatment for BRCA-mutated metastatic pancreatic cancer.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
Gastrointestinal Cancers Content
Optimizing strategies for the treatment of colorectal cancer in the biomarker era
Dr Muro, Dr Cremolini and Dr Riechelmann discuss how biomarkers can guide treatment choices for patients with colorectal cancer.
- Choose appropriate first-line treatment for patients with CRC based on biomarker testing and clinical characteristics
- Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
- Review the evidence for recent and emerging targeted therapy options for CRC
Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(1):Online ahead of journal publication
Biliary tract cancers (BTCs) are a heterogeneous group of adenocarcinomas that originate from the epithelial lining of the biliary tree and are classified into cholangiocarcinoma (CCA) and gallbladder cancer. BTC is an aggressive and rare epithelial malignancy that is usually diagnosed at an advanced stage with few effective therapeutic options.1 CCA is divided into extrahepatic and intrahepatic cholangiocarcinoma, with the extrahepatic […]
How can HER2-targeted therapies be incorporated into the management of patients with CRC?
Hear multidisciplinary team and patient perspectives on the management of HER2-positive colorectal cancer.
- Summarize how to test for HER2 amplifications in patients with CRC and how to interpret the results
- Discuss how HER2-targeted agents can be incorporated into the management of patients with CRC
- Outline how the multidisciplinary team can support patients with HER2+ CRC
What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
Watch three experts discuss testing and treatment guidelines for HER2+ colorectal cancer (CRC) and clinical trial data for HER2-targeted therapies.
- Explain the testing methods used to identify patients with human epidermal growth factor receptor 2-positive (HER2+) colorectal cancer (CRC) and the interpretation of the results
- Summarize the current guidelines for managing patients with HER2+ CRC
- Discuss the recent efficacy and safety data for HER2-targeted agents in CRC
Emerging data with immunotherapy in esophageal squamous cell carcinoma and potential impact for clinical practice
Join Dr Elizabeth Smyth as she highlights the latest clinical data on the use of immunotherapy in the management of esophageal squamous cell carcinoma (ESCC).
- Describe the efficacy data for emerging treatments, including first- and second-line immunotherapy, for ESCC
- Recall the safety data for emerging treatments for ESCC
- Discuss how the latest data for emerging treatments for ESCC could impact clinical practice
Disease burden and unmet needs of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)
Watch to learn more about the impact of GEP-NET on patients, and the need for earlier diagnosis.
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!